ICCC
Immucell·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ICCC
Immucell Corporation
A growing animal health company that develops products to improve the health and productivity of cows for the dairy and beef industries
56 Evergreen Drive
, Portland
, Maine 04103
--
Immucell Corporation was originally established in Maine in 1982 and reorganized in Delaware in 1987 with its initial public offering of common stock. Immucell's purpose is to create practical products that stand the test of science and will have a significant economic impact on the animal health, dairy and beef industries. Immucell is a publicly traded biotechnology company engaged in research and development, production and sales of products that improve animal health and increase dairy and beef production. The company's product focus includes the prevention, diagnosis and treatment of bovine diseases with important economic benefits.
Earnings Call
Q1/2025
Estimate EPS--
Actual EPS0.16
Estimate Revenue--
Actual Revenue8.07M
ImmuCell's Q1 2025: Unpacking Key Contradictions on Gross Margins, Contamination Impact, and Capital Strategy
May 21,2025 12:05
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS0.06
Estimate Revenue--
Actual Revenue6.44M
ImmuCell's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Re-Tain Approval, First Defense Sales, and Inventory Management
Aug 15,2025 11:09
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS--
Actual EPS-0.02
Estimate Revenue--
Actual Revenue5.56M
ImmuCell's Q3 2025: Contradictions Emerge on Re-Tain Approval, Inventory Management, and Contamination Impact
Nov 14,2025 11:22
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ICCC has released its 2025 Q3 earnings. EPS was reported at -0.02, versus the expected 0, missing expectations. The chart below visualizes how ICCC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ICCC has released its 2025 Q3 earnings report, with revenue of 5.51M, reflecting a YoY change of -8.41%, and net profit of -139.75K, showing a YoY change of 80.08%. The Sankey diagram below clearly presents ICCC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
